Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN).
Journal
Current opinion in supportive and palliative care
ISSN: 1751-4266
Titre abrégé: Curr Opin Support Palliat Care
Pays: United States
ID NLM: 101297402
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
Current oral treatments for neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) have limited clinical efficacy, and undesirable side-effects. Topically delivered treatments have the advantage of avoiding CNS side-effects, while relieving pain. We have reviewed treatments of neuropathic pain associated with CIPN, focusing on the Capsaicin 8% patch, which can provide pain relief for up to 3 months or longer after a single 30-60-min application. Capsaicin 8% patch is a licensed treatment in the EU/UK for neuropathic pain and shown to be safe and effective in providing pain relief for patients with CIPN. Repeated daily oral or topical administrations are not required, as with other current treatments. The side-effects are transient and restricted to the time around patch application. New evidence suggests the Capsaicin 8% patch can promote the regeneration and restoration of skin nerve fibres in CIPN, in addition to the pain relief. The Capsaicin 8% patch is now often a preferred a treatment option for localised neuropathic pain conditions, including the feet and hands in patients with CIPN. Capsaicin 8% patch can be repeated three-monthly, if needed, for a year. In addition to pain relief, it may have a disease-modifying effect.
Identifiants
pubmed: 33905384
doi: 10.1097/SPC.0000000000000545
pii: 01263393-202106000-00008
doi:
Substances chimiques
Antineoplastic Agents
0
Capsaicin
S07O44R1ZM
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-131Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130 (Pt 4):1076–1088.
Brouwers EEM, Huitema ADR, Boogerd W, et al. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol 2009; 48:832–841.
Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101:1682–1695.
Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for nonseminomatous testicular cancer. Ann Oncol 2002; 13:229–236.
Park SB, Lin CSY, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011; 16:708–716.
Bennett BK, Park SB, Lin CS-Y, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 2012; 20:2959–2967.
Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009; 144:245–252.
Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 2006; 6:5.
Pace A, Nisticò C, Cuppone F, et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer 2007; 7:550–554.
Shimozuma K, Ohashi Y, Takeuchi A, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 2012; 20:3355–3364.
Hershman DL, Weimer LH, Wang A, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011; 125:767–774.
Eckhoff L, Knoop A, Jensen MB, et al. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer 2015; 51:292–300.
Moser EC, Noordijk EM, Carde P, et al. Late nonneoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 2005; 6:122–130.
LoMonaco M, Milone M, Batocchi AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 1992; 239:199–204.
von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001; 85:823–826.
Argyriou AA, Polychronopoulos P, Koutras A, et al. Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care 2007; 16:231–237.
Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20:1767–1774.
Binder A, Stengel M, Maag R, et al. pain in oxaliplatin-induced europathy--sensitisation in the peripheral and central nociceptive system. Eur J Cancer 2007; 43:2658–2663.
Park SB, Lin CS-Y, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 2009; 132 (Pt 10):2712–2723.
Park SB, Goldstein D, Lin CS-Y, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009; 27:1243–1249.
Augusto C, Pietro M, Cinzia M, et al. Peripheral neuropathy due to paclitaxel: study of the temporal relationships between the therapeutic schedule and the clinical quantitative score (QST) and comparison with neurophysiological findings. J Neurooncol 2008; 86:89–99.
Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472–1478.
Park SB, Lin CS-Y, Krishnan AV, et al. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve 2011; 43:367–374.
Hilkens PH, Verweij J, Vecht CJ, et al. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997; 8:187–190.
Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542–5551.
Eckhoff L, Knoop AS, Jensen MB, et al. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 2013; 142:109–118.
Wang Y, Herrstedt J, Havsteen H, et al. A multicenter, nonrandomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer. BMC Cancer 2014; 14:937.
Verstappen CCP, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64:1076–1077.
Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27:3518–3525.
Ney JP, Devine EB, Watanabe JH, et al. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med 2013; 14:706–719.
Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008; 112:2802–2808.
von Delius S, Eckel F, Wagenpfeil S, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25:173–180.
Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002; 98:195–203.
Kautio A-L, Haanpää M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 2008; 35:31–39.
Aghili M, Zare M, Mousavi N, et al. Efficacy of gabapentin Gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial. Breast J 2019; 25:226–231.
Rao RD, Michalak JC, Sloan JA, et al. Efficacy of Gabapentin in the management of chemotherapy-induced peripheral Neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007; 110:2110–2118.
Salehifar E, Janbabaei G, Hendouei N, et al. Comparison of the efficacy and safety of pregabalin and duloxetine in taxane-induced sensory neuropathy: a randomized controlled trial. Clin Drug Investig 2020; 40:249–257.
Smith EML, Pang H, Cirrincione C, et al. Effect of Duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013; 309:1359–1367.
Hirayama Y, Ishitani K, Sato Y, et al. Effect of Duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 2015; 20:866–871.
Durand JP, Deplanque G, Montheil V, et al. Efficacy of Venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2012; 23:200–205.
Farshchian N, Alavi A, Heydarheydari S, et al. Comparative study of the effects of Venlafaxine and Duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018; 82:787–793.
Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011; 19:833–841.
Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical Amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 2014; 22:1807–1814.
Rossignol J, Cozzi B, Liebaert F, et al. High concentration of topical Amitriptyline for treating chemotherapy-induced neuropathies. Support Care Cancer 2019; 27:3053–3059.
Cortellini A, Verna L, Cannita K, et al. Topical menthol for treatment of chemotherapy-induced peripheral neuropathy. Indian J Palliat Care 2017; 23:350–352.
Storey DJ, Colvin LA, Mackean MJ, et al. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery. J Pain Symptom Manag 2010; 39:e2–e4.
Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of postherpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009; 25:1295–1305.
Fradkin M, Batash R, Elmaleh S, et al. Management of peripheral neuropathy induced by chemotherapy. Curr Med Chem 2019; 26:4698–4708.
Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992; 15:8–14.
Forst T, Pohlmann T, Kunt T, et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002; 39:1–6.
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107:490–502.
Webster LR, Tark M, Rauck R, et al. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 2010; 10:92.
Webster LR, Malan TP, Tuchman MM, et al. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 2010; 11:972–982.
Webster LR, Nunez M, Tark MD, et al. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with postherpetic neuralgia. BMC Anesthesiol 2011; 11:25.
Webster LR, Peppin JF, Murphy FT, et al. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. J Pain Res 2012; 5:7–13.
Webster LR, Peppin JF, Murphy FT, et al. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract 2011; 93:187–197.
Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther 2013; 10:5.
Maihofner C, Heskamp ML. Prospective, noninterventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin 2013; 29:673–683.
Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008; 7:1106–1112.
Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011; 12:99–109.
Backonja MM, Malan TP, Vanhove GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 2010; 11:600–608.
Apostolidis A, Brady CM, Yiangou Y, et al. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 2005; 65:400–405.
Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010; 59:767–774.
Facer P, Casula MA, Smith GD, et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 2007; 7:11.
Gopinath P, Wan E, Holdcroft A, et al. Increased capsaicin receptor TRPV1 in skin nerve fibres and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain. BMC Womens Health 2005; 5:2.
Matthews PJ, Aziz Q, Facer P, et al. Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 2004; 16:897–902.
Mukerji G, Yiangou Y, Agarwal SK, et al. Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. J Urol 2006; 176:797–801.
Anand P. Capsaicin and menthol in the treatment of itch and pain: recently cloned receptors provide the key. Gut 2003; 52:1233–1235.
Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Therapeutic Drug Monitoring 2009; 31:502–510.
Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012; 59:126–133.
Haanpää M, Cruccu G, Nurmikko TJ, et al. Capsaicin 8% patch versus oral Pregabalin in patients with peripheral neuropathic pain. Eur J Pain 2016; 20:316–328.
Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manag 2010; 39:1053–1064.
Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain 2014; 30:134–142.
Gavalez R, Navez M-L, Moyle G, et al. Capsaicin 8% patch repeat treatment in nondiabetic peripheral neuropathic pain: A 52-week, open-label, single-arm, safety study. Clin J Pain 2017; 33:921–931.
Gavalez R, Moyle G, Nurmikko TJ, et al. Safety, tolerability and sensory perception following capsaicin 8% patch (Qutenza) repeat treatment in peripheral neuropathic pain: STRIDE study. 2015. In: 9th Congress of the European Pain Federation (EFIC) 2015. EFIC5 -1232.
Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol 2016; 16:251.
Mankowski C, Poole CD, Ernault E, et al. Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study. BMC Neurol 2017; 17:80.
Höper J, Helfert S, Heskam M-LS, et al. High concentration capsaicin for treatment of peripheral neuropathic pain: effect on somatosensory symptoms and identification of treatment responders. Curr Med Res Opin 2014; 30:565–574.
Maihöfner CG, Heskamp MLS. Treatment of peripheral neuropathic pain by topical capsaicin: impact of preexisting pain in the QUEPP-study. Eur J Pain 2014; 18:671–679.
Martini C, Yassen A, Olofsen E, et al. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (QutenzaTM) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res 2012; 5:51–59.
Martini CH, Yassen A, Krebs-Brown A, et al. A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. Eur J Pain 2013; 17:1491–1501.
Katz NP, Mou J, Paillard FC, et al. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% capsaicin patch (Qutenza). Clin J Pain 2015; 31:859–866.
Mainka T, Malewicz NM, Baron R, et al. Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain. Eur J Pain 2015; 20:116–129.
Serrano A, Torres D, Veciana M, et al. Quantitative thermal testing profiles as a predictor of treatment response to topical capsaicin in patients with localized neuropathic pain. Pain Res Treat 2017; 2017:7425907.
Gustorff B, Poole C, Kloimstein H, et al. Treatment of neuropathic pain with the capsaicin 8% patch: quantitative sensory testing (QST) in a prospective observational study identifies potential predictors of response to capsaicin 8% patch treatment. Scand J Pain 2013; 4:138–145.
Bardo-Brouard P, Luizard C, Valeyrie-Allanore L, et al. High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series. Curr Med Res Opin 2018; 34:887–891.
Ramnarine S, Laird B, Williams LJ, et al. Investigating high-concentration 8% capsaicin patch in chronic cancer-treatment related peripheral neuropathic pain. J Clin Oncol 2016; 34: (26_suppl): 208–1208.
L.E. Marec C, Berard J, Queneuille I, et al. Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch. J Clin Oncol 2016; 34: (15_suppl): e14031–e114031.
Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol 2017; 34:162.
Anand P, Elsafa E, Privitera R, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res 2019; 12:2039–2052.
Van Acker N, Ragé M, Sluydts E, et al. Automated PGP9.5 immunofluorescence staining: a valuable tool in the assessment of small fiber neuropathy? BMC Res Notes 2016; 9:280.
Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010; 17:903–912. e44.
Koskinen MJ, Kautio A-L, Haanpää ML, et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res 2011; 31:4413–4416.
Krøigård T, Schrøder HD, Qvortrup C, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol 2014; 21:623–629.
Boyette-Davis JA, Cata JP, Zhang H, et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain 2011; 12:1017–1024.
Boyette-Davis JA, Eng C, Wang XS, et al. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 2012; 18:3180–3187.
Boyette-Davis J, Xin W, Zhang H, et al. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain 2011; 152:308–313.
Burakgazi AZ, Messersmith W, Vaidya D, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology 2011; 77:980–986.
Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008; 13:275–282.
Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 1996; 2:703–707.
Anand P, Dickenson A, Finco G, et al. Novel insights on the management of pain: highlights from the ‘Science of Relief’ meeting. Pain Manag 2019; 9:521–533.
Malmberg AB, Mizisin AP, Calcutt NA, et al. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain 2004; 111:360–367.
Ragé M, Van Acker N, Facer P, et al. The time course of CO2 laser-evoked responses and of skin nerve fibre markers after topical capsaicin in human volunteers. Clin Neurophysiol 2010; 121:1256–1266.
Papagianni A, Siedler G, Sommer C, et al. Capsaicin 8% patch reversibly reduces A-delta fiber evoked potential amplitudes. Pain Rep 2018; 3:e644.
Simone DA, Nolano M, Johnson T, et al. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 1998; 18:8947–8959.
Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain 2012; 28:101–107.
Peppin JF, Majors K, Webster LR, et al. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res 2011; 4:385–392.
Simpson DM, Brown S, Tobias J. NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70:2305–2313.